AOD-9604 GRAS Status: What It Means and What It Doesn't
AOD-9604
~925 Trial Participants
Across six clinical trials, AOD-9604 showed adverse events indistinguishable from placebo, forming the safety basis for its GRAS determination.
Stier et al., J Endocrinol Metab, 2013; Wilding, Curr Opin Investig Drugs, 2004
Stier et al., J Endocrinol Metab, 2013; Wilding, Curr Opin Investig Drugs, 2004
View as imageAOD-9604's regulatory story is frequently misrepresented. The peptide has GRAS (Generally Recognized As Safe) status as a food ingredient, a designation that is regularly conflated with FDA drug approval, clinical safety validation, or authorization for injectable use. None of those interpretations are accurate. For a full overview of this peptide, see our AOD-9604 guide.
Understanding what GRAS means, how AOD-9604 obtained it, and where the FDA has drawn explicit lines around this peptide requires separating the food regulatory framework from the drug regulatory framework. These are distinct systems with different standards of evidence, different agencies within the FDA, and different legal implications.
Key Takeaways
- AOD-9604 received GRAS status as a food ingredient based on a safety review by a qualified expert panel, not through the FDA drug approval process
- Across six clinical trials involving approximately 925 participants, AOD-9604 showed adverse events indistinguishable from placebo (Stier et al., 2013; reviewed in Wilding, 2004)
- GRAS applies only to oral consumption at food-ingredient doses (up to 1 mg/day) and does not authorize injectable use
- In December 2024, the FDA's Pharmacy Compounding Advisory Committee rejected AOD-9604 for the 503A bulk drug substances list, citing immunogenicity concerns and insufficient long-term data
- AOD-9604 has no drug approval from the FDA, EMA, TGA, or any regulatory agency worldwide
- The safety data from obesity trials showed no effect on IGF-1 levels, glucose metabolism, or insulin sensitivity, unlike full-length growth hormone (Heffernan et al., 2001)
What GRAS Actually Means
GRAS stands for Generally Recognized As Safe, a designation under sections 201(s) and 409 of the Federal Food, Drug, and Cosmetic Act. Any substance intentionally added to food is legally a "food additive" requiring premarket FDA approval, unless it is generally recognized by qualified experts as safe under its intended conditions of use. GRAS-designated substances are exempt from the food additive approval process.
There are two paths to GRAS status. The first is FDA-notified GRAS, where a company submits a formal GRAS notice (GRN) to the FDA, which reviews the evidence and issues a "no questions" letter. The second is self-affirmed GRAS, where a company convenes a panel of qualified experts who independently evaluate the evidence and determine the substance is GRAS. Self-affirmed GRAS requires no FDA review and no public filing.
The critical point: GRAS is a food safety standard. It evaluates whether a substance is safe to eat at specified doses in food products. It does not evaluate therapeutic efficacy, does not authorize medical use, and does not apply to routes of administration other than oral consumption. The safety evidence required for GRAS, while substantial, is fundamentally different from what the FDA requires for drug approval through the New Drug Application (NDA) process.
How AOD-9604 Obtained GRAS Status
AOD-9604's GRAS determination was based on the clinical trial safety data accumulated during its failed obesity drug development program. Between 2001 and 2007, Metabolic Pharmaceuticals conducted six randomized, double-blind, placebo-controlled clinical trials involving approximately 925 adult subjects.[1] The safety findings were later compiled by Stier, Vos, and Kenley in a 2013 review published in the Journal of Endocrinology and Metabolism.
The safety findings across these trials were consistent:
- No withdrawals or serious adverse events related to AOD-9604 intake occurred in any of the six studies (Stier et al., 2013)
- Adverse event rates were indistinguishable from placebo
- AOD-9604 had no effect on serum IGF-1 levels
- Oral glucose tolerance testing showed no negative effect on carbohydrate metabolism, in contrast with full-length human growth hormone[2]
- No evidence of anti-AOD-9604 antibody formation was detected in the trials that measured immunogenicity
These safety data were then evaluated by a qualified expert panel that determined AOD-9604 to be GRAS for use as a food ingredient at doses up to 1 mg/day. The panel's assessment drew on the same clinical data that had supported the obesity program, repurposing safety evidence from a failed drug program into a food ingredient application.
This pathway is unusual for a synthetic peptide. Most GRAS substances are food components with long histories of consumption (salt, vinegar, spices) or well-characterized food processing ingredients. A synthetic 16-amino-acid peptide fragment of human growth hormone receiving GRAS status is atypical, which is precisely why the distinction between food safety and drug safety matters.
What GRAS Does Not Mean
Several claims commonly made about AOD-9604's GRAS status are inaccurate:
"FDA approved": GRAS is not FDA approval. For an FDA-notified GRAS, the FDA issues a "no questions" letter, meaning it does not object to the company's safety conclusion. This is categorically different from the drug approval process, which requires demonstrated efficacy and safety through Phase I, II, and III clinical trials, manufacturing quality controls, and ongoing post-market surveillance.
"Safe for injection": The GRAS determination evaluates oral consumption of AOD-9604 in food. Route of administration fundamentally changes a substance's pharmacokinetic profile, bioavailability, and risk profile. A substance that is safe to eat may behave differently when injected subcutaneously or intra-articularly. The GRAS panel did not evaluate and did not authorize non-oral routes.
"Clinically validated": The clinical data supporting GRAS showed AOD-9604 was safe, not that it was effective for any therapeutic purpose. The largest trial (536 subjects, 24 weeks) failed to show statistically significant weight loss compared to placebo.[1] GRAS requires safety evidence. It does not require efficacy evidence.
"Approved in Australia for cartilage repair": This claim appears frequently online but is misleading. AOD-9604 is classified as a Schedule 4 (prescription-only) substance in Australia, meaning it can be prescribed by doctors and dispensed by compounding pharmacies. It has not received formal marketing approval as a pharmaceutical product from the Australian TGA for any indication. For more on the cartilage research, see our article on AOD-9604 and cartilage.
The December 2024 PCAC Decision
The gap between GRAS status and drug-use authorization became explicit in December 2024, when the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed AOD-9604 (both free base and acetate forms) for potential inclusion on the 503A bulk drug substances list.
Context matters here. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can prepare customized medications using substances on an approved "bulks list." Inclusion on this list would have allowed compounding pharmacies to legally prepare AOD-9604 formulations, including injectable forms, for individual patient prescriptions.
The PCAC rejected AOD-9604 for the 503A list. The committee cited concerns about immunogenicity risk (the potential for the peptide to trigger an immune response when injected), peptide impurity profiles, and the lack of sufficient long-term safety data for injectable administration. This rejection applies to both the free base and acetate salt forms of the peptide.
The rejection created a regulatory paradox: AOD-9604 is GRAS for eating but prohibited from pharmaceutical compounding for injection. This is not a contradiction. It reflects the fundamentally different safety standards applied to food ingredients versus injectable medications. A substance you can safely consume orally at low doses in food may carry unacceptable risks when injected at therapeutic doses, bypassing the gastrointestinal barrier and entering systemic circulation directly.
The Safety Data in Context
The clinical trial safety profile that supports GRAS deserves examination on its own terms, independent of marketing claims built on it.
Ng et al. (2000) established the foundational metabolic profile: in obese Zucker rats, 19 days of oral AOD-9604 at 500 mcg/kg reduced body weight gain by over 50% without impairing insulin sensitivity, in contrast to full-length growth hormone, which did impair insulin sensitivity.[2]
Heffernan et al. (2001) demonstrated that AOD-9604 does not bind the human growth hormone receptor and does not stimulate cell proliferation through that receptor.[3] This finding was crucial for the safety assessment because it established that AOD-9604's biological activity operates through pathways independent of the GH receptor, avoiding the metabolic disruptions (hyperglycemia, insulin resistance, tumor growth promotion) associated with growth hormone therapy.
A separate study showed that AOD-9604's lipolytic effects are mediated through beta-3 adrenergic receptor upregulation, a mechanism with a well-characterized safety profile.[4]
The human trial data, summarized by Stier et al. (2013), represents an unusually large safety dataset for a research peptide. Approximately 925 subjects received AOD-9604 across six randomized, placebo-controlled trials with treatment durations up to 24 weeks.[1] The consistency of the safety signal (no serious adverse events, no metabolic disruption, no immunogenicity) is genuinely notable for a synthetic peptide.
However, all of this data was collected using oral administration. The safety profile for subcutaneous or intra-articular injection, which is how AOD-9604 is commonly used in clinical practice today, remains uncharacterized by controlled clinical trials. The only published injection study is the Kwon and Park (2015) rabbit osteoarthritis model, which was not designed to evaluate human injection safety.[5]
How AOD-9604's Regulatory Position Compares
AOD-9604 exists in a regulatory gray zone that is not unique among peptides but is particularly well-illustrated by its history. A 2026 JAAOS review examining therapeutic peptides in orthopaedics noted that the entire peptide therapy field operates with "very limited RCTs" and that clinical use "should be framed as exploratory and hypothesis generating rather than standard of care."[6]
Compare AOD-9604's position to other peptides in the compounding landscape:
- BPC-157 was also placed in Category 2 and reviewed by PCAC. It faces similar questions about the gap between preclinical evidence and clinical validation. See our BPC-157 guide for details.
- TB-500 (thymosin beta-4) has more extensive published research but faces the same compounding restrictions. See our TB-500 overview.
- Semaglutide and tirzepatide, by contrast, completed the full NDA process with large Phase III programs and received FDA drug approval. The regulatory distance between GRAS and NDA approval is substantial.
The 2026 regulatory landscape is also shifting. In February 2026, HHS Secretary Robert F. Kennedy Jr. indicated plans to reclassify 14 of 19 peptides from Category 2 back to Category 1, which would allow 503A compounding. Whether AOD-9604 is among the 14 remains uncertain, and the reclassification has not been finalized as of March 2026.
Why the Distinction Matters
The conflation of GRAS with drug approval is not an academic concern. It has practical consequences:
For practitioners: Prescribing AOD-9604 based on "FDA GRAS status" misrepresents the regulatory basis for the peptide's safety assessment. GRAS supports oral consumption as a food ingredient. It does not provide a regulatory framework for prescribing an injectable medication.
For researchers: Citing GRAS as evidence of clinical safety for injection studies overstates the available evidence. The oral safety data is strong. The injectable safety data is absent from the published literature.
For the peptide field: Every time GRAS is marketed as equivalent to drug approval, it erodes the credibility of legitimate peptide research. The evidence for AOD-9604's safety profile is genuinely good by peptide standards. Overstating what that evidence means undermines the case for conducting the clinical trials that would actually establish injectable safety and efficacy. For context on how AOD-9604 targets fat cells through mechanisms distinct from growth hormone, the separation of activities matters for both safety and regulation.
The Bottom Line
AOD-9604 has GRAS status as a food ingredient, supported by safety data from six clinical trials involving approximately 925 participants that showed adverse events indistinguishable from placebo. This status applies exclusively to oral consumption at food-ingredient doses and does not authorize injectable use, does not constitute drug approval, and does not validate therapeutic efficacy. The FDA's PCAC rejected AOD-9604 for the 503A compounding bulks list in December 2024, explicitly distinguishing food safety from injectable drug safety. The peptide's clinical safety data for oral use is genuinely strong; the data for injectable use remains uncharacterized by controlled human trials.